FILANA THERAPEUTICS, INC.
Last · NasdaqCM$0.7316-0.0118 (-1.59%)close · yahoo · 18h ago
Market cap$35.34M48.3M sh
P/E · TTM-0.9fwd — · eps -0.87 · loss
Beta-0.66vs S&P 500
Div yield0.00%annual · TTM
52w range
$0.67$4.98
Volume251.9Ksession
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-12
- Operating Cf Burn
- Cash Runway Medium
- Accumulated Deficit High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Cash Runway Medium — Cash runway ~3.0 years
- Accumulated Deficit High — Accumulated deficit / equity 667%
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.24
Est. revenue
0
Press & signals
- GlobeNewswire
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
- GlobeNewswire
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
Documents
FormReporting forFiledFlags